Literature DB >> 10493872

Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain.

S J Mazur1, K Sakaguchi, E Appella, X W Wang, C C Harris, V A Bohr.   

Abstract

The C-terminal domain of the tumor suppressor protein p53 is the site of non-specific DNA binding. Purified p53 produced from baculovirus-infected insect cells binds preferentially to supercoiled DNA, forming bands with lower electrophoretic mobility. This non-covalent binding does not change the linking number of the DNA. An anti-p53 antibody targeting the C-terminal domain partially competes with supercoiled DNA in binding to p53, while antibodies targeted to the N terminus of p53 supershift the complex bands. A synthetic peptide corresponding to amino acid residues 319-393 of human p53 also displays preferential binding to supercoiled DNA, while a mutant peptide, which is unable to form tetramers, is inactive. The center of the equilibrium distribution of topoisomers formed by relaxation with topoisomerase I is not shifted in the presence of p53 although the distribution is broadened. The preferential binding of p53 is exhibited toward both positively and negatively supercoiled DNA. These observations are consistent with a model in which p53 binds to right-handed or left-handed strand crossings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493872     DOI: 10.1006/jmbi.1999.3064

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  14 in total

1.  Role of tumor suppressor p53 domains in selective binding to supercoiled DNA.

Authors:  Marie Brázdová; Jan Palecek; Dmitry I Cherny; Sabina Billová; Miroslav Fojta; Petr Pecinka; Borivoj Vojtesek; Thomas M Jovin; Emil Palecek
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

2.  p53 Dynamically Directs TFIID Assembly on Target Gene Promoters.

Authors:  R A Coleman; Z Qiao; S K Singh; C S Peng; M Cianfrocco; Z Zhang; A Piasecka; H Aldeborgh; G Basishvili; W L Liu
Journal:  Mol Cell Biol       Date:  2017-06-15       Impact factor: 4.272

Review 3.  Transcriptional regulation by p53.

Authors:  Rachel Beckerman; Carol Prives
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-28       Impact factor: 10.005

4.  Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.

Authors:  Jana Kasparkova; Miroslav Fojta; Nicholas Farrell; Viktor Brabec
Journal:  Nucleic Acids Res       Date:  2004-10-14       Impact factor: 16.971

Review 5.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

6.  Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

7.  Assays for the preferential binding of human topoisomerase I to supercoiled DNA.

Authors:  Zheng Yang; James J Champoux
Journal:  Methods Mol Biol       Date:  2009

8.  Mutational analysis of the preferential binding of human topoisomerase I to supercoiled DNA.

Authors:  Zheng Yang; James F Carey; James J Champoux
Journal:  FEBS J       Date:  2009-09-09       Impact factor: 5.542

9.  Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.

Authors:  Marie Brázdová; Timo Quante; Lars Tögel; Korden Walter; Christine Loscher; Vlastimil Tichý; Lenka Cincárová; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Nucleic Acids Res       Date:  2009-01-12       Impact factor: 16.971

10.  Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells.

Authors:  Marie Brázdová; Lucie Navrátilová; Vlastimil Tichý; Kateřina Němcová; Matej Lexa; Roman Hrstka; Petr Pečinka; Matej Adámik; Borivoj Vojtesek; Emil Paleček; Wolfgang Deppert; Miroslav Fojta
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.